US4182767A - Antihyperglycemic N-alkyl-3,4,5-trihydroxy-2-piperidine methanol - Google Patents

Antihyperglycemic N-alkyl-3,4,5-trihydroxy-2-piperidine methanol Download PDF

Info

Publication number
US4182767A
US4182767A US05/906,233 US90623378A US4182767A US 4182767 A US4182767 A US 4182767A US 90623378 A US90623378 A US 90623378A US 4182767 A US4182767 A US 4182767A
Authority
US
United States
Prior art keywords
acid
compound according
trihydroxy
alkyl
antihyperglycemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/906,233
Inventor
Hiromu Murai
Hiroshi Enomoto
Yoshiaki Aoyagi
Yoshiaki Yoshikuni
Masahiro Yagi
Ichiro Shirahase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of US4182767A publication Critical patent/US4182767A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Definitions

  • This invention relates to novel N-alkylpiperidine derivatives of the formula, and acid addition salts thereof: ##STR1## wherein R is alkyl of 1 to 4 carbon atoms.
  • the compounds of Formula I and their salts are novel substances which have not been described in the literature. These substances are antihyperglycemic agents and medicinally useful. The property manifests itself through inhibition of an increase of blood sugar in humans and other animals.
  • the present invention also pertains to the physiologically acceptable nontoxic acid addition salts of these basic compounds.
  • Such salts include those derived from organic and inorganic acids such as, without limitation, hydrochloric acid, hydrobomic acid, phosphoric acid, sulfuric acid, methanesulphonic acid, acetic acid, tartaric acid, lactic acid, succinic acid, citric acid, malic acid, maleic acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid, embonic acid, enanthic acid, and the like.
  • organic and inorganic acids such as, without limitation, hydrochloric acid, hydrobomic acid, phosphoric acid, sulfuric acid, methanesulphonic acid, acetic acid, tartaric acid, lactic acid, succinic acid, citric acid, malic acid, maleic acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid, embonic acid, enanthic acid, and the like.
  • This alkylation can be effected by various alternative procedures.
  • compounds of Formula II can be treated with an alkyl halide, preferably in the presence of an acid acceptor.
  • a compound of Formula II can also be N-acylated and the product then reduced to the N-alkyl compound.
  • Reductive alkylation involving the use of a carbonyl compound can also be employed. It is advantageous in the latter two instances to start with a compound of Formula II having suitably protected hydroxyl groups, i.e. R' is benzyl, benzoyl, acetyl, or the like, with the N-alkylation reaction being followed by removal of the protective groups by conventional techniques.
  • the compounds of the present invention are generally administered orally in any of the usual pharmaceutical forms. These include solid and liquid oral unit dosage forms such as tablets, capsules, powders, suspensions, solutions, syrups and the like, including sustained release preparations.
  • unit dosage form as used in this specification and the claims refer to physically discrete units to be administered in single or multiple dosage to animals, each unit containing a predetermined quantity of the piperidine derivative in association with the required diluent, carrier or vehicle.
  • the quantity of the piperidine derivative is that calculated to produce the desired antihyperglycemic effect upon administration of one or more of such units.
  • Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted diluent pharmaceutical carrier such as an edible carbohydrate material as for example, starch. Sweetening, flavoring, preservative, dispersing and coloring agents can also be present.
  • a similarly comminuted diluent pharmaceutical carrier such as an edible carbohydrate material as for example, starch.
  • Sweetening, flavoring, preservative, dispersing and coloring agents can also be present.
  • Capsules are made by preparing a powder mixture as described above and filling formed gelatin sheaths.
  • a lubricant such as talc, magnesium stearate and calcium stearate can be added to the powder mixture as an adjuvant before the filling operation;
  • a glidant such as colloidal silica may be added to improve flow properties;
  • a disintegrating or solubilizing agent may be added to improve the availability of the medicament when the capsule is ingested.
  • Tablets are made by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
  • a powder mixture is prepared by mixing the piperidine compound, suitably comminuted, with a diluent or base such as starch, sucrose, kaolin, dicalcium phosphate and the like.
  • the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
  • a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
  • the powder mixture can be run through the tablet machine and the resulting imperfectly formed slugs broken into granules.
  • the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
  • the lubricated mixture is then compressed into tablets.
  • the midicaments can also be combined with free flowing inert carriers and compressed into tablets directly without going through the granulating or slugging steps.
  • a protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.
  • Oral fluids such as syrups and elixirs can be prepared in unit dosage form so that a given quantity, e.g., a teaspoonful, contains a predetermined amount of the compound.
  • Suspensions can be formulated by dispersing the compound in a nontoxic vehicle in which it is insoluble.
  • the antihyperglycemic activity can be conveniently observed in well known and widely employed laboratory models, as for example the depression of blood sugar levels in glucose loaded rats.
  • the compounds are administered in the conventional manner to humans and other animals, in each case carefully titrating the dose to the age, condition and response of the recipient.
  • the reaction mixture is then concentrated to dryness under reduced pressure, the residue is dissolved in water and the insolubles are removed by filtration.
  • the filtrate is passed over ion exchange resin column (Dowex 50 W ⁇ 4). The column is rinsed with water and the absorved material is eluted with 0.28% aqueous ammonia.
  • This isobutyryl derivative without further purification, is reduced in 20 ml of tetrahydrofuran with 500 mg lithium aluminum hydride with heating and stirring for 2 hours.
  • the excess reactant and reaction mixture is decomposed, and concentrated in the usual fashion and the colorless oil obtained from this mixture is dissolved in a mixture of 10 ml of 47% hydrobromic acid and 10 ml of acetic acid.
  • This mixture is heated at 100° C. for one hour, diluted with 100 ml of methanol, and catalytically hydrogenated over 300 mg of 5% palladium charcoal.

Abstract

2-Hydroxymethyl-3,4,5-trihydroxy-N-alkylpiperidines and their acid addition salts are antihyperglycemic agents. A typical example is 2-hydroxymethyl-3,4,5-trihydroxy-N-methylpiperidine.

Description

DETAILED DESCRIPTION
This invention relates to novel N-alkylpiperidine derivatives of the formula, and acid addition salts thereof: ##STR1## wherein R is alkyl of 1 to 4 carbon atoms.
The compounds of Formula I and their salts are novel substances which have not been described in the literature. These substances are antihyperglycemic agents and medicinally useful. The property manifests itself through inhibition of an increase of blood sugar in humans and other animals.
The present invention also pertains to the physiologically acceptable nontoxic acid addition salts of these basic compounds. Such salts include those derived from organic and inorganic acids such as, without limitation, hydrochloric acid, hydrobomic acid, phosphoric acid, sulfuric acid, methanesulphonic acid, acetic acid, tartaric acid, lactic acid, succinic acid, citric acid, malic acid, maleic acid, sorbic acid, aconitic acid, salicylic acid, phthalic acid, embonic acid, enanthic acid, and the like.
A number of procedures are available for synthesizing the contemplated compounds of this invention. One of these involves alkylation of the corresponding N-nor-compound of Formula II wherein R' is hydrogen: ##STR2##
This alkylation can be effected by various alternative procedures. For example compounds of Formula II can be treated with an alkyl halide, preferably in the presence of an acid acceptor. A compound of Formula II can also be N-acylated and the product then reduced to the N-alkyl compound. Reductive alkylation involving the use of a carbonyl compound can also be employed. It is advantageous in the latter two instances to start with a compound of Formula II having suitably protected hydroxyl groups, i.e. R' is benzyl, benzoyl, acetyl, or the like, with the N-alkylation reaction being followed by removal of the protective groups by conventional techniques.
The compounds of the present invention are generally administered orally in any of the usual pharmaceutical forms. These include solid and liquid oral unit dosage forms such as tablets, capsules, powders, suspensions, solutions, syrups and the like, including sustained release preparations. The term unit dosage form as used in this specification and the claims refer to physically discrete units to be administered in single or multiple dosage to animals, each unit containing a predetermined quantity of the piperidine derivative in association with the required diluent, carrier or vehicle. The quantity of the piperidine derivative is that calculated to produce the desired antihyperglycemic effect upon administration of one or more of such units.
Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted diluent pharmaceutical carrier such as an edible carbohydrate material as for example, starch. Sweetening, flavoring, preservative, dispersing and coloring agents can also be present.
Capsules are made by preparing a powder mixture as described above and filling formed gelatin sheaths. A lubricant such as talc, magnesium stearate and calcium stearate can be added to the powder mixture as an adjuvant before the filling operation; a glidant such as colloidal silica may be added to improve flow properties; a disintegrating or solubilizing agent may be added to improve the availability of the medicament when the capsule is ingested.
Tablets are made by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the piperidine compound, suitably comminuted, with a diluent or base such as starch, sucrose, kaolin, dicalcium phosphate and the like. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the resulting imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The midicaments can also be combined with free flowing inert carriers and compressed into tablets directly without going through the granulating or slugging steps. A protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.
Oral fluids such as syrups and elixirs can be prepared in unit dosage form so that a given quantity, e.g., a teaspoonful, contains a predetermined amount of the compound. Suspensions can be formulated by dispersing the compound in a nontoxic vehicle in which it is insoluble.
The antihyperglycemic activity can be conveniently observed in well known and widely employed laboratory models, as for example the depression of blood sugar levels in glucose loaded rats. The compounds are administered in the conventional manner to humans and other animals, in each case carefully titrating the dose to the age, condition and response of the recipient.
The following examples are intended to further describe the method by which the compounds of this invention are produced. It should, however, be understood that the invention is not limited to the substances specifically mentioned in those examples.
EXAMPLE 1
A mixture of 7 ml of aqueous formalin, 15 ml of formic acid, 1.5 g of 2-hydroxymethyl-3,4,5-trihydroxypiperidine, m.p. 204°-205°, [α]D 25 +45° (H2 O), is heated under reflux for 20 hours. The reaction mixture is then concentrated to dryness under reduced pressure, the residue is dissolved in water and the insolubles are removed by filtration. The filtrate is passed over ion exchange resin column (Dowex 50 W×4). The column is rinsed with water and the absorved material is eluted with 0.28% aqueous ammonia. The eluate is concentrated to dryness under reduced pressure and the crystalline residue is recrystallized from ethanol to yield 2-hydroxymethyl-3,4,5-trihydroxy-N-methylpiperidine, m.p. 142°-143°, [α]D 24 +15.5° (H2 O), yield 1.2 g. Treatment with an equimolar amount of p-toluenesulfonic acid gives the corresponding p-toluenesulfonate which, in turn, is recrystallized from methanol. m.p. 198°-199°, [α]D 24 +12.2° (methanol).
EXAMPLE 2
In 10 ml of dimethylformamide are dissolved 500 mg of the starting material of Example 1. This is followed by the addition of 1.0 g of anhydrous potassium carbonate and 3 ml of methyl iodide. The mixture is stirred at room temperature for 24 hours. The reaction mixture is diluted with water and passed over ion exchange resin column (Dowex 50 W×4). The column is rinsed with water and the absorbed material is eluted with 0.28% aqueous ammonia. The eluate is concentrated to dryness under reduced pressure, extracted with hot methanol, and after insolubles are filtered off, p-toluenesulfonic acid is added. The resulting crystals, identical with the material of Example 1, are collected by filtration and recrystallized from methanol. m.p. 198°-199°; yield 0.24 g.
EXAMPLE 3
In 50 ml of dimethylformamide is dissolved 1.0 g of 2-benzyloxymethyl-3,4,5-tribenzyloxylpiperidine, m.p. 44°-47°. This is followed by the addition of 3.0 g of anhydrous potassium carbonate and 2.0 g of propyl bromide. The mixture is stirred under heating at 60°±3° for 12 hours, after which it is diluted with water and extracted with benzene. The extract as such is dissolved in a mixture of 10 ml of 47% hydrobromic acid and 7 ml of acetic acid, followed by heating at 100° C. for one hour. After cooling, 100 ml of methanol are added into the reaction mixture, and the solution is hydrogenated over 300 mg of 5% palladium-charcoal. After this catalytic reduction has been completed, the catalyst is removed by filtration and the filtrate is concentrated to dryness under reduced pressure. The residue is dissolved in water and the solution is passed over ion exchange resin column (Dowex 50 W×4). The eluate is distilled under reduced pressure to recover 205 mg of 2-hydroxymethyl-3,4,5-trihydroxy-N-propylpiperidine as colorless oil. This product is converted to the p-toluenesulfonate salt which, after recrystallization from isopropyl alcohol, melts at 208°-211°. [α]D 24 +0.4° (methanol). By substituting ethyl bromide for propyl bromide, the corresponding N-ethyl compound is obtained.
EXAMPLE 4
In 20 ml of pyridine is dissolved 1.0 g of the hydrochloride salt of the starting material of Example 3, m.p. 185°-189°. Following addition of 1.1 g of isobutyryl chloride, the solution is held at room temperature for 24 hours. The reaction mixture is then concentrated to dryness under reduced pressure, the residue is extracted with ether and the ethereal layer is washed with dilute alkali and acid. The ether is then removed by distillation to yield 1.1 g of 2-benzyloxymethyl-3,4,5-tribenzyloxy-N-isobutyrylpiperidine as colorless oil. IR spectrum: νmax film 1670 cm-1. This isobutyryl derivative, without further purification, is reduced in 20 ml of tetrahydrofuran with 500 mg lithium aluminum hydride with heating and stirring for 2 hours. The excess reactant and reaction mixture is decomposed, and concentrated in the usual fashion and the colorless oil obtained from this mixture is dissolved in a mixture of 10 ml of 47% hydrobromic acid and 10 ml of acetic acid. This mixture is heated at 100° C. for one hour, diluted with 100 ml of methanol, and catalytically hydrogenated over 300 mg of 5% palladium charcoal. Following the work-up described in Example 3, there is obtained 2-hydroxymethyl-3,4,5-trihydroxy-N-isobutylpiperidine as an oil which is converted to p-toluenesulfonate which is recrystallized from isopropanol. m.p. 192°-194°, [α]D 25 -8.3° (methanol), yield 0.46 g.

Claims (7)

What is claimed is:
1. A compound selected from the group consisting of an N-alkylpiperidine of the formula: ##STR3## wherein R is alkyl of 1 to 4 carbon atoms, and the pharmaceutically acceptable nontoxic acid addition salts thereof.
2. The compound according to claim 1 wherein R is methyl.
3. The compound according to claim 1 wherein R is ethyl.
4. The compound according to claim 1 wherein R is propyl.
5. The compound according to claim 1 wherein R is isobutyl.
6. The method of effecting an antihyperglycemic effect in humans and other animals which comprises administering thereto an antihyperglycemically effective amount of a compound according to claim 1.
7. A pharmaceutical composition comprising an antihyperglycemically effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.
US05/906,233 1977-06-25 1978-05-10 Antihyperglycemic N-alkyl-3,4,5-trihydroxy-2-piperidine methanol Expired - Lifetime US4182767A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP52075936A JPS5943459B2 (en) 1977-06-25 1977-06-25 N-alkylpiperidine derivative
JP52-075936 1977-06-25

Publications (1)

Publication Number Publication Date
US4182767A true US4182767A (en) 1980-01-08

Family

ID=13590624

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/906,233 Expired - Lifetime US4182767A (en) 1977-06-25 1978-05-10 Antihyperglycemic N-alkyl-3,4,5-trihydroxy-2-piperidine methanol

Country Status (12)

Country Link
US (1) US4182767A (en)
JP (1) JPS5943459B2 (en)
AT (1) AT365576B (en)
BE (1) BE868329A (en)
CH (1) CH633264A5 (en)
DE (1) DE2824781C3 (en)
DK (1) DK149749C (en)
FR (1) FR2420529A1 (en)
GB (1) GB1555654A (en)
IT (1) IT1104743B (en)
NL (1) NL176071C (en)
SE (1) SE430333B (en)

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260622A (en) * 1977-08-27 1981-04-07 Bayer Aktiengesellschaft Animal feedstuffs employing 3,4,5-trihydroxypiperidines
US4278683A (en) * 1978-09-09 1981-07-14 Bayer Aktiengesellschaft Saccharase inhibiting 3,4,5-trihydroxypiperidine derivatives
US4293551A (en) * 1978-08-10 1981-10-06 Bayer Aktiengesellschaft N-Amino-3,4,5-trihydroxypiperidines, their production and their medicinal use
US4312872A (en) * 1979-06-27 1982-01-26 Bayer Aktiengesellschaft 1-Alka-2,4-dienyl-2-hydroxymethyl-3,4,5-trihydroxypiperidines as inhibitors of α-glucoside hydrolases
US4328233A (en) * 1978-11-06 1982-05-04 Bayer Aktiengesellschaft α-Glucosidase inhibiting 2-hydroxymethyl-3,4,5-trihydroxy-piperidines
US4336374A (en) * 1980-01-28 1982-06-22 Nippon Shinyaku Co., Ltd. Quaternary ammonium substituted N-cinnamylpiperidines
US4336373A (en) * 1980-01-28 1982-06-22 Nippon Shinyaku Company, Ltd. Bis-piperidine compounds
US4407809A (en) * 1980-02-26 1983-10-04 Bayer Aktiengesellschaft N-phenoxy(or thio)hydrocarbon 3,4,5-trihydroxypiperidine derivatives, their use in medicine and in animal nutrition
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US4871747A (en) * 1985-12-20 1989-10-03 Bayer Aktiengesellschaft 3-Amino-4,5-dihydroxypiperidines, process for their preparation and their use
US4876268A (en) * 1988-11-03 1989-10-24 G. D. Searle & Co. Antiviral compounds and use thereof
US4937357A (en) * 1988-11-03 1990-06-26 G. D. Searle & Co. Intermediates for antiviral compounds
US4957926A (en) * 1988-12-22 1990-09-18 Monsanto Company Method of treating herpesviruses
US4973602A (en) * 1988-11-03 1990-11-27 G. D. Searle & Co. Antiviral compounds and a method of use thereas
US4999360A (en) * 1987-12-21 1991-03-12 Monsanto Company Method of inhibiting virus
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5043416A (en) * 1988-09-26 1991-08-27 Monsanto Company Method of inhibiting virus
US5043273A (en) * 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5089520A (en) * 1987-12-21 1992-02-18 Monsanto Company Method of inhibiting virus
US5103008A (en) * 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5144037A (en) * 1988-11-03 1992-09-01 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-d-glucitol derivatives
US5157116A (en) * 1988-06-02 1992-10-20 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
AU632926B2 (en) * 1990-04-27 1993-01-14 Merrell Dow Pharmaceuticals Inc. Novel nojirimycin derivatives
US5192772A (en) * 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
US5221746A (en) * 1988-11-03 1993-06-22 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5252587A (en) * 1990-04-27 1993-10-12 Merrell Dow Pharmaceuticals, Inc. N-derivatives of 1-deoxy nojirimycin
US5281724A (en) * 1990-05-07 1994-01-25 G. D. Searle & Co. Process for the preparation of 6-(n-butylamino)-6-deoxy-1,2-O-(imeihylethylidine)-a-L-Sorbofuranose and derivatives thereof
US5310745A (en) * 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US5342951A (en) * 1992-04-01 1994-08-30 G.D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5504078A (en) * 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
US5536732A (en) * 1990-04-27 1996-07-16 Merrell Pharmaceuticals Inc. N-derivatives of 1-deoxy nojirimycin
US5580884A (en) * 1993-05-13 1996-12-03 Monsanto Company Deoxygalactonojirimycin derivatives
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US6037351A (en) * 1994-01-13 2000-03-14 G. D. Searle & Co. Method of inhibiting hepatitis B virus
US6225325B1 (en) 1997-11-10 2001-05-01 G.D. Searle & Company Use of alkylated iminosugars to treat multidrug resistance
US6515028B1 (en) 1999-02-12 2003-02-04 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6809083B1 (en) 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
US20060106065A1 (en) * 1997-02-14 2006-05-18 Jacob Gary S Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
US7348000B2 (en) 1999-04-20 2008-03-25 Actelion Pharmaceuticals Ltd Therapeutic compositions and methods of treating glycolipid storage related disorders
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
US20080153896A1 (en) * 2006-07-14 2008-06-26 Gyan Chand Yadav Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
US20080161379A1 (en) * 2004-11-10 2008-07-03 Cheng Seng H Methods of Treating Diabetes Mellitus
US20080248035A1 (en) * 2005-11-08 2008-10-09 Ranbaxy Laboratories Pharmaceutical Combination
US20090042268A1 (en) * 2007-04-30 2009-02-12 Baohua Gu Iminosugar compounds with antiflavirus activity
US20090105125A1 (en) * 2006-05-09 2009-04-23 Hongmei Zhao Methods of Treating Fatty Liver Disease
US20100056602A1 (en) * 2003-05-30 2010-03-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors
US20100222384A1 (en) * 2009-02-24 2010-09-02 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
US20100222383A1 (en) * 2009-02-23 2010-09-02 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
US20100256216A1 (en) * 2007-05-31 2010-10-07 Craig Siegel 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US20100298317A1 (en) * 2007-10-05 2010-11-25 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US20100317696A1 (en) * 2009-06-12 2010-12-16 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
WO2011028779A1 (en) * 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
US20110065753A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating poxviral infections
US20110065752A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating orthomyxoviral infections
US20110184021A1 (en) * 2008-10-03 2011-07-28 Craig Siegel 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US10328061B2 (en) 2016-05-02 2019-06-25 Florida State University Research Foundation, Inc. Treatment of Zika virus infections using alpha-glucosidase inhibitors
US11369592B2 (en) 2020-02-21 2022-06-28 Florida State University Research Foundation, Inc. Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2830469A1 (en) * 1978-07-11 1980-01-24 Bayer Ag PRODUCTION OF L-DESOXY-NOJIRIMYCIN AND N-SUBSTITUTED DERIVATIVES
JPS55118415A (en) * 1979-02-28 1980-09-11 Pii Papahadojiyopo Dometoriosu Method of encapsulating biologically active substance in lipoid cell
DE2942365A1 (en) * 1979-10-19 1981-05-14 Bayer Ag, 5090 Leverkusen 2-HYDROXYALKYL-3,4,5-TRIHYDROXY- (PI) -PERIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065562A (en) * 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2656602C3 (en) * 1975-12-29 1981-11-26 Nippon Shinyaku Co., Ltd., Kyoto Method for extracting 2-hydroxymethyl-3,4,5-trihydroxypiperidine from mulberry plants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065562A (en) * 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Inouye, S. et al., J. Antibiotics, Ser. A, 19(6), 288 (1966). *
Saeki, H. et al., Chem. Pharm. Bull., 16(5), 962 (1968). *

Cited By (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639436A (en) * 1977-08-27 1987-01-27 Bayer Aktiengesellschaft Antidiabetic 3,4,5-trihydroxypiperidines
US4260622A (en) * 1977-08-27 1981-04-07 Bayer Aktiengesellschaft Animal feedstuffs employing 3,4,5-trihydroxypiperidines
US4293551A (en) * 1978-08-10 1981-10-06 Bayer Aktiengesellschaft N-Amino-3,4,5-trihydroxypiperidines, their production and their medicinal use
US4278683A (en) * 1978-09-09 1981-07-14 Bayer Aktiengesellschaft Saccharase inhibiting 3,4,5-trihydroxypiperidine derivatives
US4328233A (en) * 1978-11-06 1982-05-04 Bayer Aktiengesellschaft α-Glucosidase inhibiting 2-hydroxymethyl-3,4,5-trihydroxy-piperidines
US4312872A (en) * 1979-06-27 1982-01-26 Bayer Aktiengesellschaft 1-Alka-2,4-dienyl-2-hydroxymethyl-3,4,5-trihydroxypiperidines as inhibitors of α-glucoside hydrolases
US4336374A (en) * 1980-01-28 1982-06-22 Nippon Shinyaku Co., Ltd. Quaternary ammonium substituted N-cinnamylpiperidines
US4336373A (en) * 1980-01-28 1982-06-22 Nippon Shinyaku Company, Ltd. Bis-piperidine compounds
US4407809A (en) * 1980-02-26 1983-10-04 Bayer Aktiengesellschaft N-phenoxy(or thio)hydrocarbon 3,4,5-trihydroxypiperidine derivatives, their use in medicine and in animal nutrition
US4871747A (en) * 1985-12-20 1989-10-03 Bayer Aktiengesellschaft 3-Amino-4,5-dihydroxypiperidines, process for their preparation and their use
US5292750A (en) * 1987-12-09 1994-03-08 Nippon Shinyaku Co. Ltd. Therapeutic agents
US5192772A (en) * 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
US4999360A (en) * 1987-12-21 1991-03-12 Monsanto Company Method of inhibiting virus
US5089520A (en) * 1987-12-21 1992-02-18 Monsanto Company Method of inhibiting virus
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5157116A (en) * 1988-06-02 1992-10-20 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
US5043416A (en) * 1988-09-26 1991-08-27 Monsanto Company Method of inhibiting virus
US5221746A (en) * 1988-11-03 1993-06-22 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5310745A (en) * 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5144037A (en) * 1988-11-03 1992-09-01 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-d-glucitol derivatives
US4973602A (en) * 1988-11-03 1990-11-27 G. D. Searle & Co. Antiviral compounds and a method of use thereas
US4876268A (en) * 1988-11-03 1989-10-24 G. D. Searle & Co. Antiviral compounds and use thereof
US5476859A (en) * 1988-11-03 1995-12-19 Partis; Richard A. Antiviral compounds
US5411970A (en) * 1988-11-03 1995-05-02 G. D. Searle & Co. Method of inhibiting lentivirus
US4937357A (en) * 1988-11-03 1990-06-26 G. D. Searle & Co. Intermediates for antiviral compounds
US4957926A (en) * 1988-12-22 1990-09-18 Monsanto Company Method of treating herpesviruses
US5103008A (en) * 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5043273A (en) * 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5252587A (en) * 1990-04-27 1993-10-12 Merrell Dow Pharmaceuticals, Inc. N-derivatives of 1-deoxy nojirimycin
AU632926B2 (en) * 1990-04-27 1993-01-14 Merrell Dow Pharmaceuticals Inc. Novel nojirimycin derivatives
US5536732A (en) * 1990-04-27 1996-07-16 Merrell Pharmaceuticals Inc. N-derivatives of 1-deoxy nojirimycin
US5281724A (en) * 1990-05-07 1994-01-25 G. D. Searle & Co. Process for the preparation of 6-(n-butylamino)-6-deoxy-1,2-O-(imeihylethylidine)-a-L-Sorbofuranose and derivatives thereof
US5504078A (en) * 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
US5342951A (en) * 1992-04-01 1994-08-30 G.D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5786368A (en) * 1993-05-13 1998-07-28 Monsanto Company Deoxygalactonojirimycin derivatives
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5580884A (en) * 1993-05-13 1996-12-03 Monsanto Company Deoxygalactonojirimycin derivatives
US5656641A (en) * 1993-05-13 1997-08-12 Monsanto Company Method of inhibiting glycolipid synthesis
US5472969A (en) * 1993-05-13 1995-12-05 Monsanto Company Method of inhibiting glycolipid synthesis
US5786369A (en) * 1993-05-13 1998-07-28 Monsanto Company Method of inhibiting the surface expression of glycolipid receptors for bacteria
US5525616A (en) * 1993-05-13 1996-06-11 Monsanto Company Method of inhibiting glycolipid synthesis
US5801185A (en) * 1993-05-13 1998-09-01 Monsanto Company Method of treating Tay-Sachs disease
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US6037351A (en) * 1994-01-13 2000-03-14 G. D. Searle & Co. Method of inhibiting hepatitis B virus
US7612093B2 (en) 1997-02-14 2009-11-03 United Therapeutics Corporation Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy
US20060106065A1 (en) * 1997-02-14 2006-05-18 Jacob Gary S Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy
US6225325B1 (en) 1997-11-10 2001-05-01 G.D. Searle & Company Use of alkylated iminosugars to treat multidrug resistance
US6809083B1 (en) 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US20060264468A1 (en) * 1999-02-12 2006-11-23 United Therapeutics Corporation Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
US6515028B1 (en) 1999-02-12 2003-02-04 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
US20030220299A1 (en) * 1999-02-12 2003-11-27 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
US6747149B2 (en) 1999-02-12 2004-06-08 G. D. Searle & Co. Glucamine salts for treating hepatitis virus infections
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
US7348000B2 (en) 1999-04-20 2008-03-25 Actelion Pharmaceuticals Ltd Therapeutic compositions and methods of treating glycolipid storage related disorders
US20110190369A1 (en) * 2003-05-30 2011-08-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors
US20110190296A1 (en) * 2003-05-30 2011-08-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors
US7923467B2 (en) 2003-05-30 2011-04-12 Ranbaxy Laboratories, Inc. Substituted pyrrole derivatives and their use as HMG-CO inhibitors
US20100056602A1 (en) * 2003-05-30 2010-03-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors
US20080161379A1 (en) * 2004-11-10 2008-07-03 Cheng Seng H Methods of Treating Diabetes Mellitus
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
US9532976B2 (en) 2004-11-10 2017-01-03 Genzyme Corporation Method of lowering blood glucose
US7956198B2 (en) 2005-11-08 2011-06-07 Ranbaxy Laboratories, Limited Pharmaceutical compositions
US20080287690A1 (en) * 2005-11-08 2008-11-20 Ranbaxy Laboratories Limited Process For (3R, 5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4- [(4-Hydroxy Methyl Phenyl Amino) Carbonyl]-Pyrrol-1-Yl]-3,5-Dihydroxy-Heptanoic Acid Hemi Calcium Salt
US7671216B2 (en) 2005-11-08 2010-03-02 Ranbaxy Laboratories Limited Process for preparation of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US20090118520A1 (en) * 2005-11-08 2009-05-07 Ranbaxy Laboratories Limited Process for preparation of (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US20080248035A1 (en) * 2005-11-08 2008-10-09 Ranbaxy Laboratories Pharmaceutical Combination
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
US20090105125A1 (en) * 2006-05-09 2009-04-23 Hongmei Zhao Methods of Treating Fatty Liver Disease
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
US9556155B2 (en) 2006-05-09 2017-01-31 Genzyme Corporation Methods of treating fatty liver disease
US20080153896A1 (en) * 2006-07-14 2008-06-26 Gyan Chand Yadav Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
US20090042268A1 (en) * 2007-04-30 2009-02-12 Baohua Gu Iminosugar compounds with antiflavirus activity
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8940776B2 (en) 2007-05-31 2015-01-27 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9745294B2 (en) 2007-05-31 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US20100256216A1 (en) * 2007-05-31 2010-10-07 Craig Siegel 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US10220039B2 (en) 2007-10-05 2019-03-05 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8912177B2 (en) 2007-10-05 2014-12-16 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US20100298317A1 (en) * 2007-10-05 2010-11-25 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US9481671B2 (en) 2008-07-28 2016-11-01 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8729075B2 (en) 2008-07-28 2014-05-20 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9744153B2 (en) 2008-10-03 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US20110184021A1 (en) * 2008-10-03 2011-07-28 Craig Siegel 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
US9272996B2 (en) 2008-10-03 2016-03-01 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9044470B2 (en) 2009-02-23 2015-06-02 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
US8450345B2 (en) 2009-02-23 2013-05-28 The Chancellor, Masters And Scholars Of The University Of Oxford Iminosugars and methods of treating viral diseases
US9943532B2 (en) 2009-02-23 2018-04-17 Emergent Virology Llc Iminosugars and methods of treating viral diseases
US20100222383A1 (en) * 2009-02-23 2010-09-02 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
US9579334B2 (en) 2009-02-23 2017-02-28 Emergent Virology Llc Iminosugars and methods of treating viral diseases
US20100222384A1 (en) * 2009-02-24 2010-09-02 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
US20100317696A1 (en) * 2009-06-12 2010-12-16 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
US8426445B2 (en) 2009-06-12 2013-04-23 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
US8748460B2 (en) 2009-06-12 2014-06-10 United Therapeutics Corporation Iminosugars and methods of treating togaviral diseases
US20110065752A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating orthomyxoviral infections
WO2011028779A1 (en) * 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
US20110065754A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
US20110065753A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating poxviral infections
US10328061B2 (en) 2016-05-02 2019-06-25 Florida State University Research Foundation, Inc. Treatment of Zika virus infections using alpha-glucosidase inhibitors
US10561642B2 (en) 2016-05-02 2020-02-18 Florida State University Research Foundation, Inc. Treatment of Zika virus infections using alpha-glucosidase inhibitors
US11369592B2 (en) 2020-02-21 2022-06-28 Florida State University Research Foundation, Inc. Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors

Also Published As

Publication number Publication date
NL176071B (en) 1984-09-17
NL7805253A (en) 1978-12-28
AT365576B (en) 1982-01-25
CH633264A5 (en) 1982-11-30
ATA451778A (en) 1981-06-15
DK269178A (en) 1978-12-26
FR2420529A1 (en) 1979-10-19
SE7805329L (en) 1978-12-26
GB1555654A (en) 1979-11-14
BE868329A (en) 1978-10-16
JPS5412381A (en) 1979-01-30
IT7849760A0 (en) 1978-06-07
IT1104743B (en) 1985-10-28
FR2420529B1 (en) 1984-10-12
DE2824781A1 (en) 1979-01-04
DE2824781C3 (en) 1980-09-18
NL176071C (en) 1985-02-18
SE430333B (en) 1983-11-07
DK149749B (en) 1986-09-22
JPS5943459B2 (en) 1984-10-22
DE2824781B2 (en) 1980-01-31
DK149749C (en) 1987-03-02

Similar Documents

Publication Publication Date Title
US4182767A (en) Antihyperglycemic N-alkyl-3,4,5-trihydroxy-2-piperidine methanol
US4533668A (en) Antihyperglycemic moranoline derivatives
US4072759A (en) Novel benzylalcohol derivatives as antidiabetics and cardiotonics
IL36237A (en) Substituted benzylimidazolidinones,their preparation and pharmaceutical compositions containing them
US3954872A (en) 1-(2',6'-Dimethyl-phenoxy)-2-amino-alkanes and salts thereof
GB1569249A (en) 2-(2,2-diarylalkyl)1-azabicyclo(2.2.2)octane and compounds
EP0047536A2 (en) Substituted propylamines
HU184712B (en) Process for producing dextrorotating trans-2-substituted-5-phenyl-2,3,4,4a,5,9b,hexahydro-h-pyrido-bracket-4,3,b-bracket closedindol derivatives
JPH01131156A (en) Piperidine derivative
US3949080A (en) Compositions containing O,N-acetal and method of using same
US4336373A (en) Bis-piperidine compounds
US3459767A (en) Aminomethylindoles
EP0002672B1 (en) Substituted pyrrolidines, process for their preparation and medicaments containing them
US4336374A (en) Quaternary ammonium substituted N-cinnamylpiperidines
US4279914A (en) Thrombocyte aggregation inhibiting composition and methods
NZ187333A (en) 2-substituted-trans-2,3,4,4a,5,9b-hexahydro-1h-pyrido-(4,3-b)indoles
US3408396A (en) alpha-cyclohexyl-3, 4-disubstituted-phenyl acetamides
JPS58188879A (en) Cyproheptadine-3-carboxylic acid and ester of structurally related compound
US4052383A (en) N-diphenylalkyl-2-benzyl azacyclic compounds
US3991186A (en) Steryl-β-D-glucoside ester pharmaceutical compositions and method of use
US4140780A (en) Pharmaceutical compositions comprising N-diphenylalkyl-2-benzyl azacyclic compounds and methods for their use
DE2351281A1 (en) Aminophenylethanolamines and oxazolidines - beta-2-mimetics, beta-1-inhibitors, analgesics, uterospasmolytics, and antispastics
US3317380A (en) Process for inducing anorexia
US3542927A (en) Reduction of blood sugar levels with aminomethylindoles
US3864359A (en) 5-amino-3-ethyl-1-phenyl-4-pyrazolecarboxamides and method of preparation thereof

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE